ArticleInfection and drug resistance2026
Penicillin Allergy Labels, Broad-Spectrum Antibiotic Use, and Chronic Obstructive Pulmonary Disease Exacerbations: A Population-Based Cohort Study from China.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, and acute exacerbations drive most of its burden. Around half of exacerbations are infection related, and penicillin-class antibiotics are widely used. However, penicillin allergy labels, often inaccurate, may divert prescribing towards broader-spectrum agents and worsen outcomes. We therefore examined whether such labels are associated with antibiotic prescribing patterns and subsequent risk of COPD exacerbations in a large cohort. Methods: We conducted a retrospective cohort study in the Kunshan Aging Research with E-health (KARE) database (2016-2024). We included 14,900 patients with COPD aged ≥40 years. Exposure was a documented penicillin allergy label in the electronic medical record. Outcomes were the risk and rate of subsequent COPD exacerbations. Cox proportional hazards models estimated the association with time to first exacerbation, and negative binomial regression assessed exacerbation rates. Results: Of 14,900 patients, 722 (4.8%) had a penicillin allergy label. Overall, 2018 (13.5%) experienced at least one exacerbation during a median follow-up of 4.1 years. Compared with unlabeled patients, those with a penicillin allergy label received more broad-spectrum antibiotics and had a higher risk of exacerbations (adjusted hazard ratio 1.39, 95% confidence interval 1.17-1.65) and higher exacerbation rates (adjusted incidence rate ratio 1.56, 95% confidence interval 1.25-1.93). Conclusion: In this Chinese COPD cohort, penicillin allergy labels were associated with broader-spectrum antibiotic use and an increased burden of exacerbations. Systematic verification and de-labelling of penicillin allergy may help optimise antibiotic use and improve COPD outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.